Targeting the Distal Lung in Asthma
Tóm tắt
Inflammation of the distal lung, which consists of the small airways (internal diameter <2mm) and alveolar tissue, is an important feature of the asthma clinical syndrome comprising airway inflammation, airway hyperresponsiveness and bronchodilator-responsive expiratory airflow limitation. Support for this assertion is derived from histologic studies which have demonstrated evidence of inflammation in this anatomic compartment, along with additional studies, which have elucidated the radiologic and physiologic correlates of distal lung inflammation. Delivering inhaled drugs to this area is challenging and is dependent on a number of drug-and delivery device-related factors, as well as on a patient’s inhaler technique and bronchial anatomy. Newer chlorofluorocarbon-free formulations of inhaled corticosteroids such as hydrofluoroalkane propelled metered-dose inhalers and dry powder inhalers appear to have certain advantages with regard to drug delivery that facilitate improved drug delivery to the distal lung. Mounting evidence indicates that recognition and treatment of distal lung inflammation may be key components of appropriate asthma pharmacotherapy.
Tài liệu tham khảo
Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute; Bethesda (MD) 1997. Report No.: 97-4051
Van Vyve T, Chanez P, Lacoste JY, et al. Comparison between bronchial and alveolar samples of bronchoalveolar lavage fluid in asthma. Chest 1992; 102: 356–61
Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403–9
Howarth P. Small airway inflammation and asthma. Int J Clin Pract Suppl 1998; 96: 15–22
Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405–10
Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292–300
Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44–51
Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998; 158: 565–72
Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505–10
Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434–57
Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159: 228–34
King GG, Muller NL, Pare PD. Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. Am J Respir Crit Care Med 1999; 159: 992–1004
Okazawa M, Muller N, McNamara AE, et al. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996; 154: 1557–62
Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998; 208: 321–9
Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584–8
Irvin CG, Pak J, Martin RJ. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med 2000; 161: 50–6
Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001; 120: 94S–8S
Patel P, Mukai D, Wilson AF. Dose-response effects of two sizes of monodisperse isoproterenol in mild asthma. Am Rev Respir Dis 1990; 141: 357–60
Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996; 51: 977–80
Montreal Protocol. The Montreal Protocol on substances that deplete the ozone layer. In: Final Act (Nairobi: UNEP, 1987). Fed Regist 1994, 98
Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120: 89S–93S
Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002; 109: S447–60
Laube BL. In vivo measurements of aerosol dose and distribution: clinical relevance. J Aerosol Med 1996; 9 Suppl. 1: S77–91
Leach CL. Enhanced drug delivery through reformulating MDIs with HFA propellants: drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V proceedings. Buffalo Grove (IL): Interpharm Press, 1996: 133–144
Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209–26
Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346–53
Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400μ, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800μ, for the treatment of moderate asthma. Chest 1999; 115: 343–51
Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87: 405–11
Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258–67